PRIMARY STUDY
Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report
Key Findings: Treprostinil given subcutaneously for patients with pulmonary arterial hypertension can cause injection site pain. In this case review, two patients had a reduction in pain and erythema by using topical cannabidiol (CBD) prior to injections.
Type of Study: Meta-analysis
Study Sample Size: 2
Study Result: Positive
Research Location(s): United States
Year of Pub: 2023
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype III
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Safety Profile
Established Protocol: Effective dose
Route of Administration: Topical
Cannabinoid Ratio: (CBD) 0 
Dosage Form: salve
Dosing Regimen: CBD 500 mg
Treatment Duration: Prior to placing the catheter or injection.
Clinical Relevance: Topical CBD reduced subcutaneous injection insertion site pain.
Citation: Brewer J and Kimber A. Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report. Front Med (Lausanne). 2023; 10:1188083. doi: 10.3389/fmed.2023.1188083
Authors: Brewer J, Kimber A
